New Mutation Facilitates Spread of Drug-Resistant Malaria
Research identifies a novel genetic mutation increasing malaria parasites' treatment resistance.
1Critical Resistance Issue in Malaria Treatment
Decades-old malaria drugs used in sub-Saharan Africa are becoming less effective as parasites develop reduced sensitivity. A Brown University-led team conducted whole-genome analysis of 157 parasite samples collected from Uganda between 2016-2024. Published in Nature Medicine, the study suggests mutations in the px1 gene may be responsible for rising resistance. Malaria remains a major cause of death in the region, with resistance threatening control efforts.
2Discovery of the PIN Mutation
Researchers identified a mutation cluster in the px1 gene consisting of three amino acid changes and two deletions (DNA sequence losses), named PIN. The mutation was found to be passed down through generations nearly intact, indicating rapid recent spread. First detected in 2008, the mutation reached 84% prevalence in northern Uganda and 55% in eastern Uganda by 2024. This accelerated spread raises significant public health concerns.
3Drug Resistance Test Results
Laboratory tests confirmed malaria parasites with the PIN mutation showed reduced sensitivity to lumefantrine (a component of the common artemether-lumefantrine combination therapy) and other antimalarials. Control parasites with disabled px1 genes responded more strongly to treatments. However, no clear effect was observed regarding artemisinin resistance. Prior to this, no validated genetic markers existed for lumefantrine resistance.
4Regional Spread and Global Status
Analysis of 2001-2015 global genetic databases revealed the PIN mutation was extremely rare then, with only five detections in neighboring Democratic Republic of Congo and Kenya. Notably, it was absent from 2010 Ugandan samples in the dataset. Current cross-border spread remains unclear due to data gaps. Researchers emphasize the need to incorporate this mutation into surveillance systems to monitor its expansion.
5Clinical Implications and Next Steps
The study currently only demonstrates laboratory-level changes in drug susceptibility. Clinical impacts on actual malaria patients remain unknown. Researchers stress the urgent need for systems predicting when drugs will become ineffective and for developing new treatments to maintain effective malaria control. These findings could significantly impact global malaria eradication programs and public health strategies in endemic regions.
6Unique Resistance Mechanism
While Kelch13 (K13) gene mutations were previously linked to artemisinin resistance, no verified molecular markers existed for lumefantrine resistance. Lead author Karamoko Niare notes the px1 mutation could fill this critical knowledge gap. The mutation's rapid spread tendency presents new challenges for malaria control. Strengthening genetic surveillance capabilities in affected regions has become a priority for public health authorities.
7Call for Public Health Emergency Action
Researchers advocate declaring a public health emergency due to the mutation's spread rate and drug resistance potential. Adapting malaria control programs in sub-Saharan Africa to this new threat is crucial. WHO reported 247 million malaria cases and 619,000 deaths globally in 2021. Rising drug resistance could worsen these figures, particularly in high-burden regions where treatment options are already limited.
8Future Research and Hope
The team emphasizes need for further research to understand px1's exact resistance mechanism, which could reveal new drug targets. Establishing early detection systems in unaffected regions might slow the mutation's spread. These findings may mark the beginning of a new era in malaria fight, prompting global collaboration to develop next-generation treatments before resistance becomes widespread.
Original article: Science Latest — Yeni Mutasyon, İlaç Dirençli Sıtmanın Yayılmasını Kolaylaştırıyor